Drilldown: Medicines
Appearance
Medicines > onset
:
30–60 min
or
BP and symptomatic LUTS improvement within 1-2 weeks
or
Urinary concentration adequate within hours 
:
30–60 min
or
BP and symptomatic LUTS improvement within 1-2 weeks
or
Urinary concentration adequate within hours 
Use the filters below to narrow your results.
CNS stimulant (1) ·
NDRI (1) ·
PDE5 Inhibitor (1) ·
Psychostimulant (1) ·
[[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]] (2) ·
[[:Category:Antibacterials|Antibacterial]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (2) ·
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (2) ·
[[:Category:Nitrofurans|Nitrofuran]] (1) ·
[[:Category:Urinary_anti-infectives|Urinary anti-infective]] (1)
None (2) ·
Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) ·
Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
'"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) ·
'"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) ·
'"`UNIQ--vote-000008A1-QINU`"', '"`UNIQ--vote-000008A2-QINU`"' (1) ·
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) ·
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)
None (1) ·
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
100 mg PO BID × 5 days (Macrobid) for cystitis; 50-100 mg HS for chronic prophylaxis (1) ·
50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1)
'''Avoid at term (38-42 weeks) and during labor''' (risk of neonatal hemolytic anemia, especially with G6PD deficiency); generally safe in earlier pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Category B (1) ·
Category C (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 5 results in range #1 to #5.

